Palantir Slides, Vertex Pharmaceuticals Surges, DoorDash Lower Despite Earnings Beat
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
On this episode of Stock Movers:
- Palantir (PLTR) shares slide by the most in nearly a year after its financial results and projections failed to live up to investors’ lofty expectations. The company described rising demand for artificial intelligence software as a “ravenous whirlwind” and bumped its 2025 revenue forecast on Monday to about $3.9 billion from about $3.75 billion.
- Vertex Pharmaceuticals (VRTX) shares fall after the company reported adjusted earnings per share for the first quarter that missed expectations. Analysts are mixed about the launch of the non-opioid pain medication Journavx and Alyftrek, a triple modulator for cystic fibrosis
- DoorDash (DASH) drops after announcing two multibillion-dollar acquisitions: London-based delivery company Deliveroo Plc for £2.9 billion and hospitality tech company SevenRooms Inc. for $1.2 billion. Alongside the deals, DoorDash also issued a strong orders outlook for the current quarter and posted better-than-expected gross order value for the first three months of the year in a statement on Tuesday.
See omnystudio.com/listener for privacy information.